ROCKWOOL A/S
ROCKWOOL A/S – transactions in connection with share buy-back programme
ROCKWOOL A/S – transactions in connection with share buy-back programme
Company announcement
for ROCKWOOL A/S
Release no. 24 – 2025
to Nasdaq Copenhagen
23 April 2025
ROCKWOOL A/S – transactions in connection with share buy-back programme
As mentioned in announcement no. 07/2025, ROCKWOOL A/S has initiated a share buy-back programme which will run from 7 February 2025 until 5 February 2026. During this period, the Company will buy own shares for up to a maximum of 150 MEUR.
The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation.
The following transactions have been executed during the period 16 – 22 April 2025:
Date | Number of B shares | Average purchase price B shares (DKK) | Aggregate amount, B shares (DKK) |
[Accumulated, last announcement] | 869,500 | 242,866,656 | |
16 April 2025 | 13,000 | 281.09 | 3,654,170 |
22 April 2025 | 14,000 | 274.12 | 3,837,680 |
Accumulated under the programme (B shares) | 896,500 | 250,358,506 |
With the transactions stated above, ROCKWOOL A/S owns 6,116,630 B shares corresponding to 2.83 percent of the Company’s total share capital.
An overview showing the transaction data for the period 16 – 22 April 2025 is enclosed.
Further information:
Kim Junge Andersen
Senior Vice President, CFO
ROCKWOOL A/S
+45 46 55 80 15
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
MoonLake Immunotherapeutics AG25.4.2025 22:05:00 CEST | Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
T-knife Therapeutics25.4.2025 19:00:00 CEST | Press release
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
Zymeworks Inc.25.4.2025 19:00:00 CEST | Press release
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Sequana Medical NV25.4.2025 18:00:00 CEST | Press release
Press release: Transparency Notification from Shareholders
Sanoma Corp25.4.2025 17:30:00 CEST | Press release
SANOMA CORPORATION: ACQUISITION OF OWN SHARES 25 April 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom